• Users Online: 499
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 53  |  Issue : 3  |  Page : 93-100

The clinical significance of ARID1A mutations in gastric cancer patients


1 Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital; Department of Surgery, School of Medicine, National Yang-Ming University, Taipei City, Taiwan
2 Department of Surgery, School of Medicine, National Yang-Ming University; Department of Oncology Taipei Veterans General Hospital, Taipei City, Taiwan
3 Department of Surgery, School of Medicine, National Yang-Ming University; Department of Pathology Taipei Veterans General Hospital, Taipei City, Taiwan

Correspondence Address:
Dr. Wen-Liang Fang
Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Beitou District, Taipei City 11217
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/fjs.fjs_66_19

Rights and Permissions

Background: ARID1A is a key component of the SWI/SNF chromatin remodeling complex, which has been identified in various cancers. Loss of ARID1A expression is correlated with poor prognosis in gastric cancer (GC); however, the clinical relevance of ARID1A mutations in GC has not yet been reported. Materials and Methods: A total of 518 GC patients receiving gastrectomy were enrolled. The analysis of 13 mutations of the ARID1A gene using mass spectrometric single-nucleotide polymorphism genotyping technology was conducted. The clinicopathological features of GC with and without ARID1A mutations were compared. Results: Among the 518 GC patients, 59 (11.4%) had ARID1A mutations. For diffuse-type GC, patients with ARID1A-mutated tumors were older and had fewer poorly differentiated tumors, fewer incidence of Epstein–Barr virus infection, a higher likelihood of ARID1A expression loss, more microsatellite instability-high tumors, a lower prevalence of peritoneal recurrence, and better survival rates than those with ARID1A nonmutant tumors. For intestinal-type GC, patients with ARID1A-mutant tumors had more PI3K/AKT pathway genetic mutations than patients with ARID1A nonmutant tumors. Multivariate analysis showed that ARID1A mutations are an independent prognostic factor in diffuse-type GC. Conclusion: ARID1A mutations are associated with a better prognosis in diffuse-type GC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed341    
    Printed15    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    

Recommend this journal